1. Home
  2. Research
  3. Research Groups
  4. Molecular Pathology of Cancer Group

Molecular Pathology of Cancer Group

Search for publications

Only original articles, editorials, guidelines.

  • O'Shaughnessy J, Bidard FC, Neven P, Casalnuovo ML, Aftimos P, Saura C, Harbeck N, Carey LA, Curigliano G, Garcia-Saenz JA, Abad MF, Paula L, Park YH, Ozyilkan O, Munoz M, Barrett E, Cao S, Chawla A, Jhaveri KL.

    Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.

    npj Breast Cancer . 12(1): .

    [doi:10.1038/s41523-026-00950-z]

  • Perez-Gracia JL, Mellado B, Hansen AR, Alonso-Gordoa T, Gomez-Roca C, Løvendahl Eefsen R, Negrier S, Suárez C, Lee JL, Hussain A, Pedrazzoli P, Moreno V, Rodriguez-Vida A, Sosman JA, Waddell T, Bedke J, Park SH, Sznol M, Spychaj L, Andersson E, Julien-Laferriere A, Cheng WY, Watson C, Silva AP, Heichinger C, Staedler N, Sleiman N, Dejardin D, Boetsch C, Evers S, Vardar T, Ardeshir-Tandon C, Dorado Pérez J, Charo J, Keshelava N, Kraxner A, Teichgräber V, Powles T.

    Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

    Journal for ImmunoTherapy of Cancer . 14(4): .

    [doi:10.1136/jitc-2025-012466]

  • Capdevila J, Hernando J, Molina-Cerillo J, Plana Serrahima M, Taberna Sanz M, Castelo B, Álvarez-Escolá C, Carmona-Bayonas A, Ballester Navarro I, Iglesias L, Bover M, Garcia-Alvarez A, Lavernia J, Yayá Tur R, Ruiz S, Baste N, Lorenzo-Lorenzo I, Sanchez-Hernandez A, Sanz-Garcia E, Marquina G, Nuciforo P, Elguero B, Grande E, Alonso-Gordoa T.

    Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.

    Nature Communications . 17(1): .

    [doi:10.1038/s41467-026-71155-y]

  • Ruz-Caracuel I, Alonso-Gordoa T, Hernández S, Hernando J, Rodrigo-Calvo MT, Jimenez-Fonseca P, Quiceno-Arias HD, Lorenzo-Lorenzo I, Bella-Cueto MR, Iglesias C, Cameselle-Teijeiro JM, Capdevila J.

    SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer.

    Revista Espanola de Patologia . 59(2): 100859-100859. Number of citations: 2

    [doi:10.1016/j.patol.2026.100859]

  • Moreno-Moreno E, Caniego-Casas T, Ruz-Caracuel I, Carretero-Barrio I, Cabezas-López E, Cortés-Salgado A, Mendiola M, Redondo A, Muriel A, Hardisson D, Palacios J, Pérez-Mies B.

    MDM4 amplification as a potential predictor of risk of recurrence in early-stage low-grade endometrial carcinoma.

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER . 36(4): 104563-104563.

    [doi:10.1016/j.ijgc.2026.104563]

  • Barretina-Ginesta MP, Madariaga A, Gil-Martín M, Ramchandani A, Pardo M, Sanchez-Heras AB, Churruca C, Guerra-Alia EM, Madroñal C, Fernandez-Plana J, Herrero A, Dotor E, Esteban C, Quindós-Varela M, Romeo M, Gost E, Bermejo MJ, Fernandez-Chacón C, Ferrer N, Gomez-Raposo C, Tort SC, Eichbaum M, Sehouli J, Woopen H.

    Addressing unmet needs in long-term survivors of ovarian cancer (ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI): insights from a Spanish cohort.

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER . 36(4): 102758-102758.

    [doi:10.1016/j.ijgc.2025.102758]

  • Lázaro-Navas I, Mur-Molina B, Villalobos-Baeza EB, Cortés-Salgado A, Pailos RH, Díaz-Soto EM, Fernández-Pardo TE, López-González L, Valcárcel-Linares D.

    Effectiveness of radiofrequency therapy combined with pelvic floor muscle training in breast cancer survivors with genitourinary syndrome of menopause: a study protocol.

    European Journal of Obstetrics & Gynecology and Reproductive Biology . 320: 115010-115010.

    [doi:10.1016/j.ejogrb.2026.115010]

  • Garcia-Carbonero R, Benavent M, Jimenez-Fonseca P, Alonso-Gordoa T, Teulé A, Custodio A, Tafuto S, La Casta A, Spada F, López C, Ibrahim T, Iranzo V, García-Alfonso P, González-Flores E, Villanueva Silva MJ, Grande E, Panzuto F, Crespo G, Navarro M, Castellano D, Hernando J, Morales-Herrero R, Iglesias Álvarez G, Soldevilla B, Capdevila J.

    Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).

    JOURNAL OF CLINICAL ONCOLOGY . 44(9): 774-786. Number of citations: 3

    [doi:10.1200/JCO-25-01808]

  • Tolosa P, García-Fructuoso I, Pascual T, Martínez-Sáez O, Cejalvo JM, Servitja S, Fernández Abad M, Benitez Fuentes JD, Brasó-Maristany F, Sanfeliu E, Lema L, Ruano Y, Parrilla L, Roncero AM, Cobos MÁ, Díaz I, Centelles López KA, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E.

    Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.

    BREAST CANCER RESEARCH AND TREATMENT . 216(2): .

    [doi:10.1007/s10549-026-07931-7]

  • Cerbone L, Roviello G, Calabrò F, Taha T, Grande E, Binz K, Kanesvaran R, Pirstuk A, Fiala O, Molina-Cerrillo J, Alonso-Gordoa T, Rizzo A, Pichler R, Myint ZW, Poprach A, Facchini G, Bohuslav M, Studentova H, Morelli F, Buchler T, Mennitto A, Tural D, Formisano L, Orejana I, Catalano M, Buti S, Monteiro FSM, Soares A, Gupta S, Massari F, Santoni M.

    Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?

    Frontiers in Immunology . 17: 1667155-1667155.

    [doi:10.3389/fimmu.2026.1667155]

  • Makker V, Colombo N, Casado A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Yonemori K, Kim YM, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kristeleit R, Nishio S, Suzuki S, Guerra Alía EM, Sanli UA, Selle F, Shikama A, Martínez Rodríguez JL, Arik Z, Arican A, Sebastianelli A, Yu Z, McKenzie J, Kruger S, Meng R, Okpara CE, Lorusso D.

    Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.

    Journal for ImmunoTherapy of Cancer . 14(2): . Number of citations: 1

    [doi:10.1136/jitc-2025-013713]

  • Chong AS, Roca C, Morales-Sánchez P, Dorca E, Barea V, Ruz-Caracuel I, Valderrabano P, Rovira C, Jou C, Bouron-Dal Soglio D, Chernock RD, Torrezan GT, Pusztaszeri M, Cameselle-Teijeiro JM, Matias-Guiu X, Alvarez CV, Salvador H, Wasserman JD, Leandro-García LJ, Foulkes WD, Andrés-León E, Casano-Sancho P, Rivera B.

    Tracing the molecular route to progression in miRNA-biogenesis-defective thyroid lesions.

    JCI Insight . 11(3): .

    [doi:10.1172/jci.insight.198338]

  • González-Martínez S, Palacios J, Carretero-Barrio I, Fernández-Lanza V, Cortés-Salgado A, Román J, Matias-Guiu X, Gatius S, Cortés J, Pérez-Mies B.

    Single-nucleus RNA sequencing identifies a novel tenogenic heterologous differentiation in endometrial carcinosarcomas: implications for diagnosis and tumor classification.

    JOURNAL OF PATHOLOGY . 268(2): 227-242.

    [doi:10.1002/path.70003]

  • Casas Gállego VR, Perez Muñoz I, Sanz Pascual MDC, Gonzalez Lizan F, Reguero Callejas ME, Delgado Martínez I.

    Extra-axial chordoma in the distal fibula and the importance of ankle reconstruction.

    World Journal of Surgical Oncology . 24(1): .

    [doi:10.1186/s12957-025-04187-1]

  • Borrego MR, López-Bravo DP, Vila MM, Pérez-García JM, Fernández M, Tormo SB, García-Saenz JÁ, Lema L, Garau I, Cortez P, Torres AA, Conejo EA, Calvo I, Ferrer N, Blancas I, Amillano K, Santasusagna S, Benderra MA, Alcalá-López D, Antonarelli G, Sampayo-Cordero M, Llombart-Cussac A, Cortés J.

    Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study

    EUROPEAN JOURNAL OF CANCER . 233: 116161-116161. Number of citations: 1

    [doi:10.1016/j.ejca.2025.116161]

  • Fizazi K, Saad F, Alonso-Gordoa T, Zurawski B, Barthélémy P, Voog E, Cutuli HJ, Buchler T, Ye D, Castellano D, Kwiatkowski M, Arslan C, Richardet M, Alifrangis C, Goh JC, Vianna K, Han W, Hatano K, Todenhöfer T, Retz M, Srivastava A, Jin C, Gupta S, Trandafirescu G, Campos A, Lee CW, van Kooten Losio M, Subudhi SK.

    Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.

    LANCET ONCOLOGY . 27(1): 68-78. Number of citations: 2

    [doi:10.1016/S1470-2045(25)00566-2]

  • Ruz-Caracuel I.

    Recent advances in pituitary tumors following the 2022 WHO classification.

    Endocrinologia Diabetes y Nutricion . 73(1): 501747-501747.

    [doi:10.1016/j.endien.2026.501747]

  • Pistilli B, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Jañez NM, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Tsurutani J, Kalinsky K, Liedke PER, Carroll D, Khan S, Rugo HS, Xu B, Bardia A.

    Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study.

    ANNALS OF ONCOLOGY . : .

    [doi:10.1016/j.annonc.2025.12.017]